Importance

Loading Importance Indicators...

Abstract

This invention is directed to compounds of the formula: ##STR1## wherein j is 0 or 1; k is 0 or 1; m is 0 or 1; n is 0 or 1; W is --O--; --S(.dbd.O).sub.t --, where t is 0, 1, or 2; or --N(R.sup.3)--; where R.sup.3 is --H, --(C.sub.1 -C.sub.3) alkyl, --OR.sup.12, phenyl, or benzyl; R.sup.C and R.sup.D have the same meaning as R.sup.A and R.sup.B, except that at least one of R.sup.C and R.sup.D must be --H; and the other variables are defined as set forth in the specification. The invention is also directed to pharmaceutical compositions comprising the above compounds and to methods of treating a subject suffering from a disease, disorder or condition mediated by the PDE4 isozyme, the method comprising administering a therapeutically effective amount of a compound as described above. The invention is particularly directed to methods of treating inflammatory, respiratory and allergic diseases and conditions, especially asthma; chronic obstructive pulmonary disease (COPD) including chronic bronchitis, emphysema, and bronchiectasis; chronic rhinitis; and chronic sinusitis.

Loading the Abstract Image...

First Claim